Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.68 |
| ▸ | NPY2R | P49146 | 10/20 | 0.61 |
| ▸ | NPY4R | P50391 | 8/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.61 |
| ▸ | NPY1R | P25929 | 8/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30938249 | 1.00 | CALCR (0.68) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29370426 | 1.00 | CALCR (0.67) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30938250 | 1.00 | CALCR (0.67) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30028547 | 0.97 | CALCR (0.65) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31507665 | 0.94 | CALCR (0.63) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30495665 | 0.91 | CALCR (0.65) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30495756 | 0.90 | CALCR (0.64) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31182717 | 0.90 | CALCR (0.68) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30887555 | 0.90 | CALCR (0.66) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30887977 | 0.90 | CALCR (0.64) | CALCRKEAP1MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235553-A1 | HUMANIN, COLIVELIN AND DERIVATIVES FOR THE TREATMENT OF HEMORRHAGIC SHOCK | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-07 | — | — | WO | claimed |
| CN-121927028-A | Polypeptide for protecting pulmonary vascular endothelial cells and relieving lung injury and application thereof | 复旦大学附属中山医院 | 2026-04-28 | — | — | CN | disclosed |
| US-20250345391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEPSIS | CHILDRENS HOSPITAL MED CT (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240350587-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12064467-B2 | Systems and methods for delivery of humanin or other peptides | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240156900-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2023235553-A1 | HUMANIN, COLIVELIN AND DERIVATIVES FOR THE TREATMENT OF HEMORRHAGIC SHOCK | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023235553-A1 | HUMANIN, COLIVELIN AND DERIVATIVES FOR THE TREATMENT OF HEMORRHAGIC SHOCK | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-116688097-A | Application of Humann polypeptide and analogue thereof in preventing and treating premature ovarian failure caused by pre-pubertal chemotherapy | 昆明医科大学第一附属医院 | 2023-09-05 | — | — | CN | disclosed |
| CN-115838412-A | New application of Humanin polypeptide analogue | 昆明医科大学第一附属医院 | 2023-03-24 | — | — | CN | disclosed |
| US-20220211654-A1 | MATERIALS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| CN-114288387-A | Application of Humanin derivative HNG in preparation of heart failure treatment drugs | 重庆医科大学 | 2022-04-08 | — | — | CN | disclosed |
| EP-3965747-A1 | MATERIALS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350587-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | MTPN, NLN, MFN2 | CALCR 4257/4885NPY2R 1335/4885NPY4R 1780/4885 |
| US-20240156900-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | MTPN, NLN, MFN2 | CALCR 4257/4885NPY2R 1335/4885NPY4R 1780/4885 |
| US-12064467-B2 | Systems and methods for delivery of humanin or other peptides | MTPN, NLN, MFN2 | CALCR 4257/4885NPY2R 1335/4885NPY4R 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.